Experts from the University of California (USA) has developed a drug that helps to cope with triple negative breast cancer. This type of cancer is virtually untreatable by conventional methods. Now, in cancer patients with this disease have a chance for a long life, experts say.
The drug got the name of LAS17. Once in the body, it binds with the enzyme glutathione-S-transferase Pi1, produced by cancer. As a result, the enzyme activity reduced, and the rate of cancer development is much slower.
This allows you to increase the effectiveness of traditional methods of treatment: hormonal, radiotherapy and chemotherapy. The first experiment on animals confirm the effectiveness of the product. Among its advantages there is a lack of side effects.